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ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common lethal human 
malignancies worldwide and its advanced status is frequently resistant to conventional 
chemotherapeutic agents and radiation. We evaluated the cytotoxic effect of the 
orally bioavailable dual PI3K/mTOR inhibitor, NVP-BGT226, on a panel of HCC cell 
lines, since hyperactivated PI3K/Akt/mTOR signaling pathway could represent a 
biomolecular target for Small Inhibitor Molecules in this neoplasia. We analyzed the 
drug activity in both normoxia and hypoxia conditions, the latter playing often a 
relevant role in the induction of chemoresistance and angiogenesis.
In normoxia NVP-BGT226 caused cell cycle arrest in the G0/G1 phase of the cell 
cycle, induced apoptosis and autophagy at low concentrations. Interestingly the drug 
inactivated p-Akt and p-S6 at < 10 nM concentration.
In hypoxia NVP-BGT226 maintained its cytotoxic efficacy at the same 
concentration as documented by MTT assays and Western blot analysis. Moreover, 
the drug showed in hypoxia inhibitory properties against angiogenesis by lowering 
the expression of the transcription factor HIF-1α and of VEGF.
Our results indicate that NVP-BGT226 has a potent cytotoxic effect on HCC cell 
lines also in hypoxia condition, thus emerging as a potential candidate for cancer 
treatment in HCC targeted therapy.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a disease 
increasing in incidence worldwide [1–5]. One of the most 
prevalent reasons for the high mortality rate in patients 
with HCC is the lack of effective treatment, especially for 
patients with advanced disease [6]. Sorafenib, approved 
for the treatment of resistant and advanced HCC, has 
shown low response rate and serious side effects such 
as hypertension, rash, fatigue, and hand and foot skin 
reactions [7–9]. For this reason, an effective and well-
tolerated pharmaceutical profile for the treatment of 
advanced HCC is requested to introduce new, potential 
and therapeutic approaches.
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The phosphoinositide 3-kinase (PI3K)/Akt/mTOR 
signaling pathway is one of the most frequently 
dysregulated signaling cascades in human malignancies, it 
displays oncogenic potential and it is implicated in a wide 
variety of different neoplasms, including HCC [10, 11]. 
Phosphorylation of Akt activates several substrates, 
including the mTOR complex 1 (mTORC1), and induces 
subsequent phosphorylation of downstream targets such 
as the ribosomal S6 kinase. The activation of mTORC1 
results in increased translation and protein synthesis 
[12]. A second complex comprising mTOR, known as 
mTORC2, more recently described, appears to act as a 
feedback loop via Akt phosphorylation on Ser 473 [13].
Given the emerging importance of PI3K/Akt 
signaling pathway for tumorigenesis in the liver, the 
potential use of PI3K/Akt pathway modulators is 
increasingly considered as a targeted therapeutic choice.
Furthermore PI3K/Akt signaling pathway plays 
also an important role in the regulation of angiogenesis 
[14, 15], that represents a crucial event in tumor evolution 
and metastasis. One of the most important stimuli for 
angiogenesis is hypoxia, that represents a common feature 
of the tumor microenvironment, since human solid tumors 
are invariably less well-oxygenated than the normal 
tissues from which they arose [16]. Sustained hypoxia 
in a growing tumor is one of the most important stimuli 
for increased VEGF production and this growth factor, 
as well as its receptor, is up-regulated in HCC, whose 
overexpression is inversely related with the prognosis and 
survival of HCC patients [17].
The frequent activation of the PI3K pathway in 
cancer and its crucial role in cell growth and survival has 
made it a much relevant desired target for pharmacologic 
intervention. The first PI3K pathway-targeted agents 
approved for cancer treatment were the “rapalogs” 
Everolimus (RAD001) and Temsirolimus (CCI779), both 
with the capacity to inhibit the functional protein complex 
mTORC1. In addition to these agents, other classes of 
PI3K/mTOR pathway inhibitors have been developed: 
one is composed by dual inhibitors of PI3K and mTOR 
(and thus mTORC1 and mTORC2). NVP-BGT226 
(BGT226) (Novartis Pharma AG, Basel, Switzerland), an 
imidazoquinoline derivative, belong to this class being an 
ATP-competitive dual PI3K/mTORC1/C2 inhibitor: it is a 
potent pan-class I PI3K inhibitor (p110α, β, δ, and γ, with 
a preference for the α-isoform -wild type and mutated-) 
and is a mTORC1/2 catalytic inhibitor [18, 19].
It has been recently demonstrated that PI3K/Akt 
signaling pathway regulates VEGF and HIF-1α expression, 
and inhibitors targeting PI3K p110α decrease both VEGF 
expression and angiogenesis in HCC in vitro model [20].
Therefore, in this study, we wanted to investigate 
the antitumor activity of the orally bioavailable dual 
PI3K/mTOR inhibitor, NVP-BGT226 (BGT226), on a 
panel of hepatocellular carcinoma (Mahlavu, SNU475, 
SNU449, HepG2 and Hep3B) cell lines in either normoxia 
and hypoxia condition. All these HCC cell lines have an 
hyperphosporylated Akt, as previously demonstrated by 
us and by other research groups [21–25]. Mahlavu lack 
the expression of PTEN and also SNU449 have a low 
expression of this protein [21, 26].
BGT226 is in phase I/II clinical trials for the 
treatment of advanced solid tumors, such as breast, head 
and neck, endothelial cells and lung cancer [11, 18, 26–29] 
and this is the first work showing the in vitro activity of 
this PI3K/Akt signaling pathway inhibitor in HCC cells. 
Treatments of HCC cells with BGT226 caused in normoxia 
condition cell cycle arrest in the G0/G1 phase of the cell 
cycle, and induced apoptosis and autophagy at very low 
doses. Moreover, BGT226 showed in hypoxia conditions 
inhibitory properties against angiogenesis by inhibiting the 
expression of HIF-1α and VEGF. Our results indicate that 
the dual PI3K/mTOR inhibitor, BGT226, is cytotoxic for 
HCC cell lines in normoxia and in hypoxia condition. It 
is also a potent inhibitor of the expression of HIF-1α and 
VEGF and may represent a new promising therapeutic 
approach in the treatment of hepatocellular carcinoma.
RESULTS
BGT226 affects cell viability and is cytotoxic in 
hepatocarcinoma cell lines
To determine whether the dual PI3K/mTOR inhibitor 
BGT226 could affect the viability of HCC, Mahlavu, 
SNU475, SNU449, HepG2 and Hep3B cells were incubated 
in the presence of increasing concentrations of the drug for 
either 24 or 48 h. Cell viability rates were then analyzed by 
MTT assays. The experiments documented that already at 
24 h all the cell lines were very sensitive to BGT226 (data 
not shown). After 48 h of treatment cell viability impairment 
was more evident, with an IC50 value ranging from 0.55 μM 
for Mahlavu to 1.35 μM for HepG2 cells (Figure 1A, 1B). It 
should be noted that the range of sensitivity is very close and 
no significant differences are observable among the different 
cell lines. This observation strengthen the hypothesis that this 
signaling pathway is altered in a similar way in these cell 
lines that can be used as a representative panel.
We also investigated the effects of the drug on cell 
cycle progression. Mahlavu and Hep3B cells were treated 
for 24 h with increasing concentrations of the drug and 
stained with Propidium Iodide (PI) for the Muse™ Cell 
Analyzer. In both cell lines the analysis showed a significant 
increase in the G0/G1 phase of the cell cycle (Figure 1C). 
No significant differences appeared between the activity of 
BGT226 in Mahlavu and Hep3B cells, being the percentage 
of cells blocked in G0/G1 phase very similar.
BGT226 induces both apoptosis and autophagy
Previous studies demonstrated that in solid tumors 
BGT226 can induce apoptosis [11, 30]. In order to 
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establish whether decreased cell viability was related to 
apoptosis in HCC cell lines, we treated Mahlavu, SNU475 
and Hep3B cells for 24 h with increasing concentrations 
of the drug, and we analyzed the expression levels of 
PARP, Caspase 9 and the effector Caspase 7. After 24 h of 
treatment, 0.5 μM BGT226 was able to induce cleavage 
of PARP, Caspase 9 and Caspase 7 (Figure 2A). We then 
analyzed apoptosis by Annexin-V staining in Mahlavu, 
SNU475 and Hep3B cells treated with increasing 
concentrations of BGT226 for 24 h. The drug induced 
concentration-dependent apoptosis in all the three cell 
lines (Figure 2B), with a more relevant effect in Mahlavu 
and SNU475 than in Hep3B.
After 24 h of treatment with increasing concentrations 
of BGT226, chromatin condensation was observable in 
Mahlavu cells by DAPI staining (Figure 2C).
To further analyze whether the intrinsic pathway 
(i.e., caspase-9) was involved in the proapoptotic action 
of BGT226 in HCC cells, we examined the effect of the 
pan-caspase inhibitor Z-VAD-fmk, whose activity has 
already been analyzed in different tumor cell lines [31, 
32], administered alone and in combination with BGT226 
for 24 h in Mahlavu and SNU449 cells. As shown in 
Figure 2D, Z-VAD-fmk 75 μM significantly inhibited 
the cell death induced by BGT226 used at the IC50 value, 
indicating that the apoptotic process mediates BGT226 
cytotoxicity.
To evaluate whether the treatment with BGT226 
could induce autophagy, we analyzed the expression of 
microtubule associated protein 1 light chain 3 (LC3) A / B I 
(non lipidated) and its conjugated form LC3A/B II 
(lipidated) and the expression of another autophagy-
related protein, SQSTM1/p62 by Western blot. Lysosomal 
degradation of autophagosomes leads to a decrease in 
SQSTM1 levels during autophagy; conversely, autophagy 
inhibitors stabilize SQSTM1 levels [33]. The levels of 
LC3A/B II gradually increased whereas p62 decreased 
in SNU475 and Mahlavu, in a dose dependent manner 
(Figure 3A), thus showing the activation of autophagy 
after BGT226 administration.
To verify whether autophagy was either a cell 
survival or a cell death mechanism, we used the autophagy 
inhibitor Chloroquine (CQ), since it has recently been 
reported its ability to block autophagy by inhibiting 
lysosomal proteases and autophagosome-lysosomal fusion 
events [34, 35]. SNU475 and Mahlavu cells were treated 
Figure 1: BGT226 affects cell viability and cell cycle in HCC cell lines. A. MTT assay of HCC cells treated with increasing 
concentrations of BGT226 for 48 h. SD was less than 8%. B. IC50 values of BGT226 at 48 h of treatment in Mahlavu, SNU449, SNU475, 
Hep3B and HepG2 cell lines are reported. C. Mahlavu and Hep3B cells were treated with increasing concentrations of BGT226 for 24 h. 
BGT226 treatment resulted in an increase in cells in the G0/G1 phase and in a decrease in cells in S and G2/M phase. CTRL, control 
(untreated) cells. Asterisks indicate significant differences compared with CTRL (*p < 0.05). SD was less than 10%.
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Figure 2: BGT226 induces apoptosis in HCC cell lines. A. Western blot analysis of Mahlavu, SNU475 and Hep3B cell lines treated 
for 24 h with increasing concentrations of the drug, ranging from 0.1 to 0.5 μM. Twenty-five μg of protein were blotted to each lane. β-Actin 
served as a loading control. B. Analysis of Annexin-V positive cells after BGT226 treatment using the Muse™ Cell Analyzer in Mahlavu, 
SNU475 and Hep3B cells. The analysis was performed after 24 h of treatment with increasing concentrations of BGT226. Results are the 
mean of three different experiments ± SD. Asterisks indicate significant differences compared with CTRL (*p < 0.05). C. DNA staining 
of Mahlavu cells with the fluorescent dye DAPI is reported. In these cells, treated with increasing concentrations of the BGT226 ranging 
from 0.1 to 0.5 μM, aspects of nuclear chromatin condensation (arrows), representing the apoptotic mode of cell death, are observable. Bar: 
10 μm. D. Annexin-V analysis after BGT226 treatment, alone and in combination with the pan caspase inhibitor Z-VAD-fmk, in Mahlavu 
and SNU449 cells. The analysis was performed after 24 h of treatment with BGT226 at the IC50value and Z-VAD-fmk at 75 μM.
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for 24 h with 0.5 μM BGT226 and 10 μM CQ, alone 
and in combination, and expression of LC3A/B I-II was 
assessed by Western blot. BGT226 induced the lipidation 
of LC3I to LC3II and the addition of CQ further increased 
LC3A/B II levels (Figure 3B).
We also found that autophagy could protect HCC 
cells from the cytotoxic effects of BGT226. This was 
assessed by MTT Assays, after treating SNU475 and 
Mahlavu cells with 0.5 μM BGT226 and 10 and 25 μM CQ 
for 24 h. We used BGT226 at the concentration of 0.5 μM 
to avoid a too high cytotoxicity that would result with a 
higher concentration of the drug and that would prevent 
the possibility to observe the additional effect of the two 
drug combination. CQ, when used alone, displayed only 
limited cytotoxic effects against SNU475 and Mahlavu 
cells. However, when it was combined with BGT226, it 
was possible to detect an increased cytotoxicity in both 
cell lines (Figure 3C). To further confirm the protective 
Figure 3: BGT226 induces autophagy. A. Western blot analysis documenting increased expression of the fast-migrating (lipidated) 
LC3A/B and decreased expression of SQSTM1/p62 in SNU475 and Mahlavu cell lines treated with BGT226. Twenty-five μg of protein 
were blotted to each lane. β-Actin documented equal lane loading. B. Western blot analysis documenting the effects of chloroquine (CQ) 
on LC3A/B lipidation in SNU475 and Mahlavu cell lines treated with increasing concentrations of BGT226 for 24 h. β-actin served as a 
loading control. C. MTT assay showing the activity of CQ, alone and in combination with BGT226, in Mahlavu and SNU475 cells after 
24 h of treatment. D. MTT assay showing the activity of 3-MA, alone and in combination with BGT226, in SNU475, Mahlavu, Hep3B and 
HepG2 cells after 24 h of treatment. The results are the mean of three different experiments ± SD. Asterisks indicate statistically significant 
differences with respect to treatment with BGT226 alone (*p < 0.05).
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role of autophagy from the cytotoxic effect of BGT226 we 
also used a different autophagy inhibitor, 3-Methyladenine 
(3-MA) which blocks at an early stage autophagy by 
inhibiting the class III phosphoinositide 3-kinase (PI3K) 
[36]. 3-MA alone did not affect significantly cells after 
24 h of treatment. However, when it was combined with 
0.5 μM BGT226, it showed an increased cytotoxicity in all 
HCC cell lines (Figure 3D).
BGT226 inhibits the PI3K/Akt/mTOR signaling 
pathway in HCC cells in normoxia and hypoxia 
conditions
Since in non-small cell lung cancer cell lines the 
BGT226-dependent modulation of PI3K/Akt/mTOR signal 
axis has been demonstrated [11], we determined whether this 
drug also affected downstream signal transduction factors 
that promote PI3K/Akt/mTOR-mediated cell survival. 
When the five cell lines were treated with increasing 
concentrations of BGT226 for 1 h in normoxic conditions, 
the phosphorylation of Akt and its substrate GSK3 α/β, of 
mTORC1/2 and of mTORC1 substrate S6 was effectively 
suppressed in a dose-dependent manner (Figure 4A).
Growth in hypoxia condition can result in a tumor 
with a more aggressive and malignant phenotype, with 
a very different sensitivity to drugs of the therapeutic 
protocol [37–39].
Thus, we first compared the activity of BGT226 
in the modulation of PI3K/Akt/mTOR pathway in 
normoxia or hypoxia conditions with the contemporary 
administration of the drug at very low concentrations 
(1-5-10 nM) for 1 h in Mahlavu and SNU475 
(Figure 4B). BGT226 was able to suppress both Akt 
and S6 phosphorylation. It is worth noting the very 
potent dephosphorylating effect of this drug at < 10 nM 
concentration and this effect appeared to be independent 
from the normoxia or hypoxia state of the cells. To better 
investigate a possible PI3K hyperactivation in hypoxia 
conditions, we collected the five HCC cell lines after 24 h 
hypoxia and compared the expression of phosphorylated 
and total Akt with normoxic cells. As showed in Figure 4C, 
the expression levels of activated and total Akt in 
normoxia and hypoxia remained unchanged. To further 
explore the efficacy of BGT226 in hypoxia, Mahlavu, 
SNU475 and SNU449 were exposed for 24 h in hypoxia, 
followed by 1 h treatment with increasing concentrations 
of BGT226. Results showed that BGT226 was able to 
suppress Akt phosphorylation also in 24 h hypoxic cells 
(Figure 4D).
To further assess this observation, MTT assays in four 
HCC cell lines were performed. Mahlavu, SNU475, Hep3B 
and SNU449 were incubated in the presence of increasing 
concentrations of the drug for 24 h, in normoxia or hypoxia 
conditions. Results showed similar activity of the drug in 
normoxia as compared with hypoxia (Figure 4E).
Autophagy is induced by BGT226 in 
hypoxia condition
The administration of BGT226 in hypoxia condition 
gradually increased the expression levels of LC3A/B II and 
decreased the expression of SQSTM1/p62 in SNU475 and 
Mahlavu cells in a dose dependent manner (Figure 5A).
To obtain a comparison with the normoxia data, we 
also used Chloroquine (CQ) to inhibit autophagy either 
alone or in combination with BGT226. Thus, SNU475 
and Mahlavu cells were treated for 24 h in hypoxia 
with BGT226 0.5 μM and CQ 10 μM, alone and in 
combination, and expression of LC3A/B I-II was assessed 
by Western blot. As shown in Figure 5B, BGT226 induced 
the lipidation of LC3A/B I to LC3A/B II. The addition of 
CQ further increased the expression of LC3 A/B II.
Finally, as in normoxia, we also found that 
autophagy protects HCC cells from the cytotoxic effects 
of BGT226. This was assessed by MTT assays, after 
treating SNU475 and Mahlavu cells with BGT226 0.5 μM 
and CQ 10 and 25 μM for 24 h. CQ alone displayed only 
limited cytotoxic effects against SNU475 and Mahlavu 
cells. However, when it was combined with BGT226, it 
was possible to detect an increased cytotoxicity in both 
cell lines (Figure 5C). To extend the analysis concerning 
the protective role of autophagy also in hypoxia we 
used the autophagy inhibitor 3-MA. The inhibitor alone 
did not affect cell growth of Mahlavu and Hep3B after 
24 h of treatment. However, when it was combined with 
0.5 μM BGT226, it was possible to detect an increased 
cytotoxicity in both cell lines (Figure 5D).
Therefore we were able to assess the same effect 
of BGT226 also in hypoxia condition and the same role 
of autophagy in both conditions, normoxia and hypoxia.
BGT226 inhibits the expression of HIF-1α 
and VEGF in HCC cells
A low oxygen level is characteristic of solid tumors 
and represents a negative prognostic factor for cancer 
patient survival. The response of cancer cells to hypoxia 
drives neo-angiogenesis but also enhances malignant 
phenotype development and an increased production of 
hypoxia-inducible factor (HIF-1), containing HIF-1α and 
HIF-1β subunits, that acts as a key regulatory transcription 
factor responsible for adaptive cellular changes. HIF-1α 
protein is suppressed in cells under normoxic conditions 
(20–22% O2) and its expression is rapidly induced by 
hypoxic conditions (1–2% O2). In humans, HIF-1 has 
been shown to up-regulate expression of genes affecting 
a range of target areas of physiology, and it is a major 
regulator of VEGF, an important growth factor involved 
in angiogenesis.
Therefore we first evaluated the induction of 
HIF-1α in HCC cells at increasing times of hypoxia. As 
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Figure 4: BGT226 modulates PI3K/Akt/mTOR pathway in HCC cells and is sensitive either in normoxia and hypoxia 
conditions. A. Western blot analysis for phosphorylated/total Akt, GSK3 α/β, mTOR and its substrate S6 in Mahlavu, SNU475, SNU449, 
Hep3B and HepG2 cells treated for 1 h with increasing concentrations of BGT226 in normoxic condition. B. Western blot analysis 
for phosphorylated/total Akt and S6 in Mahlavu and SNU475 cells after 1 h of normoxia or hypoxia conditions with the concomitant 
administration of increasing concentrations of BGT226. C. Western blot analysis for phosphorylated/total Akt in HCC cells harvested after 
24 h of normoxia or hypoxia conditions. CTRL: control, N: normoxia, H: hypoxia. D. Western blot analysis for phosphorylated/total Akt 
in Mahlavu, SNU475 and SNU449 cells pre-treated for 24 h in normoxia or hypoxia conditions, and then treated for 1 h with increasing 
concentrations of BGT226. For all the experiments twenty-five μg of protein was blotted to each lane. β-Actin served as a loading control. 
E. MTT Assay showing the activity of BGT226 in HCC cells after 24 h of treatment, in normoxia and hypoxia conditions.
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shown in Figure 6A, the expression of HIF-1α increased 
progressively along with exposure to hypoxia.
Treatment with increasing concentrations BGT226 
under hypoxic conditions showed a significant, dose 
dependent inhibition of HIF-1α in Mahlavu and Hep3B 
cells (Figure 6B). The efficacy of BGT226 in hypoxic 
condition was further confirmed after treatment of 24 h 
and detection for VEGF levels. Increasing concentrations 
of the drug suppressed or reduced the expression of 
this crucial member of the hypoxia microenvironment 
(Figure 6B).
DISCUSSION
The PI3K/AKT/mTOR pathway has a critical 
role in the pathogenesis of HCC, and it has emerged to 
be an important therapeutic target for anticancer drug 
development, since many clinical studies have indicated 
that activation and deregulation of PI3K/Akt pathway play 
roles in various human cancers [40, 41].
The panel of HCC cells chosen for this work 
displays different levels of activated Akt and therefore 
it is an ideal model for the dual PI3K/mTOR inhibitor 
NVP-BGT226.
Several mechanisms may be responsible for the 
activation of PI3K/Akt in HCC. The high frequency of 
the PI3K p110α gene (PIK3CA) mutations and/or its up-
regulation in patients with a shorter survival is responsible 
for the Akt hyperactivation found in HCC with poor 
prognosis [42]. Moreover, impaired expression of PTEN 
could be involved in the regulation of PI3K/Akt activity. 
Ruan et collaborators demonstrated that overexpression of 
PTEN significantly reduced the proliferation of HepG2, 
and the same cell line transfected with PTEN were more 
sensitive to sorafenib in terms of its ability to inhibit 
proliferation and to induce apoptosis [43].
A reduction in cell viability was observed in our 
panel of HCC cell lines treated with low concentrations 
of BGT226 for 48 h. Among the five tested cell lines, 
Mahlavu and SNU449 cells were the most sensitive to 
Figure 5: Modulation of autophagy by BGT226 in hypoxia condition. A. Western blot analysis documenting increased 
expression of the fast-migrating (lipidated) LC3A/B and decreased expression of SQSTM1/p62 in SNU475 and Mahlavu cell lines treated 
with BGT226 for 24 h in hypoxia condition. β-Actin documented equal lane loading. B. Western blot analysis documenting the effects of 
chloroquine (CQ) on LC3A/B lipidation in SNU475 and Mahlavu cell lines treated in hypoxia with increasing concentrations of BGT226 
for 24 h. β-actin served as a loading control. C. MTT Assay showing the activity of CQ, alone and in combination with BGT226, in Mahlavu 
and SNU475 cells after 24 h treatment in hypoxia condition. D. MTT Assay showing the activity of 3-MA, alone and in combination with 
BGT226, in Mahlavu and Hep3B cells after 24 h treatment in hypoxia condition. The results are the mean of three different experiments 
± SD. Asterisks indicate statistically significant differences with respect to BGT226 alone (*p < 0.05).
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the drug, with an IC50 value of nearly 0.5 μM, even if the 
difference is not so relevant when compared to Hep3B, 
being the IC50 value of 1.22 μM.
Cell cycle arrest in cancer cells is a major indicator 
of anticancer activity and has been implicated in different 
cancers, including HCC [44]. The anti-proliferative effect 
of BGT226 induced after 24 h cell cycle arrest in the G0/G1 
phase. The cytotoxicity of the drug was mediated by the 
apoptotic process, as demonstrated by both Annexin V 
analysis and DAPI-stained samples and with a pan-caspase 
inhibitor that blocked BGT226-induced apoptosis.
Autophagy is a response to growth limiting 
conditions, such as nutrient depletion, hypoxia and 
the presence of cytotoxic drugs [45] and it may trigger 
increased induction of apoptosis in cells [46]. The 
correlation between autophagy and tumorigenesis has been 
explored extensively, but whether autophagy acts as a pro-
tumorigenic or anti-tumor player in tumor development 
and cancer therapy, still has to be fully elucidated [47, 48]. 
However, autophagy has been found to be associated with 
drug resistance in HCC [35].
We documented that BGT226 also induced 
autophagy in HCC cells and its inhibition by CQ and 
by 3-MA further sensitized HCC cells to the cytotoxic 
effects of 24 h of BGT226. These findings suggest that 
in HCC cells autophagy could have a tumor protecting 
role when neoplastic cells are treated with PI3K/Akt/
mTOR inhibitors. Due to these properties CQ has been 
also studied as a potential agent in cancer therapy, since 
autophagy could act as a cell-survival pathway in cancer, 
in agreement with our data [49–51].
In this work we demonstrated for the first time that in 
HCC models BGT226 has anticancer effects in HCC cells, 
and these effects act on the proliferation, apoptosis and 
angiogenesis. Therefore, we hypothesized that its role could 
not only reflect therapeutic potential in a normoxic condition 
Figure 6: BGT226 and the modulation of HIF-1α and VEGF in HCC cells in hypoxia conditions. A. Western blot analysis 
documenting the expression of  hypoxia-inducible factor 1α (HIF-1α) in Mahlavu, SNU475 and SNU449 at increasing exposure times of normoxia 
(N) and hypoxia (H) samples. β-actin served as a loading control. B. Western blot analysis showing the expression of HIF-1α and vascular 
endothelial growth factor (VEGF) in Mahlavu and Hep3B cells treated with increasing concentrations of BGT226. The expression of HIF1α and 
VEGF is revealed at 6 h and 24 h of hypoxia, respectively. CTRL: control, N: normoxia, H: Hypoxia. β-actin served as a loading control.
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for tumor cells, but it could also improve therapeutic options 
for HCC also in a hypoxic microenvironment.
The dual PI3K/mTOR inhibitor, BGT226, has 
been investigated for the treatment of hematological 
malignancies, such as acute lymphoblastic leukemias [19, 
52], alone, in combination or in comparison with other 
drugs such as gefitinib or NVP-BEZ235 in different solid 
tumor models, including non-small cell lung cancer, head 
and neck squamous cell carcinoma, pancreatic cancer, 
multiple myeloma and breast cancer [11, 26, 29, 53].
Gefitinib treated cells displayed increased levels 
of phosphorylation in IGF-1R and Akt, indicating the 
intensified activation of this cancer-associated signaling 
pathway in Mahlavu cells [54]. Therefore the efficacy of 
BGT226 acquires relevance in gefitinib resistant models 
such as Mahlavu cells.
Since BGT226 has been used with efficacy in this 
HCC model, it may therefore be considered as a potential 
therapeutic options in other solid tumors such as colon, 
ovary or stomach.
Until now, BGT226 activity has been analyzed only 
in normoxia condition. Therefore in these solid neoplasms 
BGT226 may have a potential role in developing new 
therapeutic strategies where the hypoxic conditions could 
limit drug efficacy.
In this study we observed that BGT226 was 
capable at very low concentrations to induce Akt and S6 
dephosphorylation and also reduced the phosphorylation of 
mTORC1/2 after 1 h of drug exposure. Interestingly BGT226 
maintained these properties also in hypoxia condition.
Tumor hypoxia leads to resistance to radiotherapy 
and anticancer chemotherapy as well as predisposing 
for increased tumor metastases [16]. In HCC it has been 
reported that hypoxia enhances proliferation [55, 56] and 
suppresses differentiation and apoptosis [57, 58], resulting 
in tumor malignancy.
Therefore hypoxia cause cellular changes that can 
result in a more clinically aggressive phenotype and it is 
of interest the development of therapeutic strategies that 
can overcome this resistance.
BGT226 appears to be an interesting candidate for 
this strategy, since it was effective in both normoxia and 
hypoxia conditions as demonstrated by MTT assay and 
Western blot analysis with the suppression of cell viability 
and the inhibition of the PI3K/Akt/mTOR signaling 
pathway. As expected autophagy in both conditions 
resulted activated after drug exposure.
HIF-1 plays a central role as the main regulator of 
the hypoxic transcription response [59, 60]. Increased 
concentrations of HIF-1 in the proteome of a hypoxic cell 
result from increased transcription of HIF-1α and HIF-
1β genes and decreased HIF-1α protein degradation, an 
example of hypoxia-mediated post translational control 
[61, 62]. This transcription factor has been shown to have 
several transcriptional targets including VEGF, the best-
characterized angiogenic growth factor [63].
Our results showed the inhibitory activity of 
BGT226 in the expression of HIF-1α and VEGF in 
hypoxia condition. Increasing concentrations of the 
drug suppressed in a dose dependent manner both these 
crucial members of hypoxia microenvironment, thus 
hypothesizing also its potential anti-angiogenic role.
HCC is a highly-vascularized, neoplastic disease with 
rapid growth and repetitive vascular invasion, and the process 
of angiogenesis could be a target for novel prognostic and 
therapeutic approaches to HCC, involving VEGF [64].
In conclusion, BGT226 inhibits the PI3K/Akt/
mTOR pathway and shows potent cytotoxic activity by 
inhibiting cell growth and proliferation in parallel with 
increasing caspase-dependent and independent apoptosis.
BGT226 may therefore represent a potential 
anticancer agent in HCC for its capability to target the 
hyperactivated PI3K/Akt/mTOR signaling pathway 
and to inhibit, in hypoxia microenvironment, increased 
translation and synthesis of proteins such as HIF-1α and 
VEGF, from which may depend tumor progression.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium (DMEM), 
RPMI-1640 medium, fetal bovin serum (FBS), nonessential 
amino acids (NEAA), penicillin and streptomycin were from 
Lonza (Lonza Milano SRL, Milan, Italy). For cell viability 
determination, Cell Proliferation Kit I (MTT) was purchased 
from Roche Applied Science (Basel, Switzerland). Annexin 
V/7-AAD and cell cycle kits were from Merck-Millipore 
(Darmstadt, Germany). NVP-BGT226 and Z-VAD-FMK 
were provided by Selleck Chemicals (Houston, TX, USA). 
Antibodies to total Akt-1, Ser473 p-Akt-1 and VEGF 
were from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). HIF-1α antibody was provided by BD Biosciences 
Pharmigen, while all the other antibodies were from Cell 
Signaling Technology (Danvers, MA, USA), including 
the rabbit secondary antibody, SQSTM1/p62 (#5114) and 
Cleaved Caspase-7 (Asp198, #9491) antibodies. The mouse 
secondary antibody, 3-Methyladenine (3-MA), Chloroquine, 
1,4-Diazabicyclo[2.2.2.]octane (DABCO) and 4’,6 
diamidino-2-pheny-lindole (DAPI) were from Sigma Aldrich 
(Milan, Italy). Signals were detected with the ECL Plus 
reagent purchased from Perkin Elmer (Boston, MA, USA).
Cell culture and western blot analysis
The HCC cell line Mahlavu was kindly provided 
by dr. Rengul Cetin-Atalay (Bilkent University, Ankara, 
Turkey) [65–67] while Hep3B (ATCC no: HB-8064), 
HepG2 (ATCC no: HB-8065) SNU449 (ATCC no: 
CRL-2234) and SNU475 (ATCC no: CRL-2236) were 
obtained from ATCC. Mahlavu, Hep3B and HepG2 
were maintained in DMEM medium supplemented 
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with 10% FBS, 2 mM L-Glutamine, 0.1 mM NEAA, 
100 U/ml penicillin and 100 μg/ml streptomycin. 
SNU449 and SNU475 cell lines were maintained in 
RPMI-1640 medium supplemented with 10% FBS, 
2 mM L-Glutamine, 100 U/ml penicillin and 100 μg/
ml streptomycin. For normoxic condition, all cells 
were cultured in a 37°C humidified incubator and an 
atmosphere of 5% CO2 in air. For hypoxic condition, 
cells were cultured in a CO2 incubator (Forma™ 
Series II Water Jacket CO2, Thermo Scientific, 
USA) maintained at 94% N2, 5% CO2 and 1% O2 for 
indicated times of treatments. Western blot analysis was 
performed by standard methods as described elsewhere 
[68–70].
Cell viability analysis
MTT (3-[4,5-Dimethylthythiazol-2-yl]-2,5-Dip-
he nyltetrazolium Bromide) assays were performed to 
assess the sensitivity of cells to drugs, as previously 
described [71].
Cell cycle and apoptosis analysis
Cell cycle analysis was performed using the Muse™ 
Cell Analyzer (Merck Millipore, Milan, Italy). In brief, 
after 24 h of treatment, cells were harvested, centrifugated 
at 300 x g for 5 min and washed once with 1X PBS. After 
fixing them with 70% ethanol for at least 3 h at –20°C, 
cells were centrifuged at 300 x g for 5 min, washed once 
with 1X PBS and then 200 μl of Muse™ Cell Cycle 
reagent was added to each tube with an incubation of 30 
min at room temperature in the dark. Samples were then 
analyzed according to the instrument protocol.
Moreover, analysis of apoptosis was performed by 
Annexin-V/7-AAD-Assay using Muse™ Cell Analyzer. 
In brief, cells treated with increasing concentrations of 
BGT226 were harvested by trypsinization after 24 h of 
treatment, and a 100 μl cell suspension was labeled for 
20 min in the dark with the same volume of the Muse™ 
Annexin-V & Dead Cell reagent (Merck Millipore). 
Subsequently, quantitative detection of Annexin-V/7-
AAD positive cells was performed with the Muse™ Cell 
Analyzer.
DAPI staining
Cell nuclear morphology was evaluated by 
fluorescence microscopy following DAPI staining. Cells 
were treated with BGT226 for 24 h in normoxia condition. 
The cells were washed with PBS (pH 7.4), cytocentrifuged, 
fixed with 4% paraformaldehyde/PBS and stained for 3 min 
with 1 μg/ml DAPI. The cells were then washed with PBS, 
specimens were embedded in glycerol with antifading agent 
(DABCO) and examined under Zeiss Axiophot fluorescence 
microscope (Zeiss, Germany).
Statistical evaluation
The data are presented as mean values from three 
separate experiments ± SD. Data were statistically 
analyzed by a Dunnet test after one-way analysis of 
variance (ANOVA) at a level of significance of P < 0.05 
vs control samples [72].
ACKNOWLEDGMENTS
This work was supported by a MIUR FIRB 2010 
grant to SC (RBAP10Z7FS_002), MIUR FIRB 2011 grant 
to AMM (RBAP11ZJFA_001), by a MIUR PRIN-2009 
grant to SC and by current research funds IRCCS Burlo 
Garofolo to GZ.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Shirabe K, Toshima T, Taketomi A, Taguchi K, 
Yoshizumi T, Uchiyama H, Harimoto N, Kajiyama K, 
Egashira A, Maehara Y. Hepatic aflatoxin B1-DNA adducts 
and TP53 mutations in patients with hepatocellular carci-
noma despite low exposure to aflatoxin B1 in southern 
Japan. Liver Int. 2011; 31:1366–1372.
2. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, 
Aishima S, Maehara Y. The predictors of microvascular 
invasion in candidates for liver transplantation with hepa-
tocellular carcinoma-with special reference to the serum 
levels of des-gamma-carboxy prothrombin. J Surg Oncol. 
2007; 95:235–240.
3. Shirabe K, Kajiyama K, Harimoto N, Tsujita E, 
Wakiyama S, Maehara Y. Risk factors for massive 
 bleeding during major hepatectomy. World J Surg. 2010; 
34:1555–1562.
4. Bruix J, Llovet JM. Prognostic assessment and evaluation 
of the benefits of treatment. J Clin Gastroenterol. 2002; 
35:S138–142.
5. Zhuang PY, Wang JD, Tang ZH, Zhou XP, Yang Y, 
Quan ZW, Liu YB, Shen J. Peritumoral Neuropilin-1 and 
VEGF receptor-2 expression increases time to recurrence 
in hepatocellular carcinoma patients undergoing curative 
hepatectomy. Oncotarget. 2014; 5:11121–11132.
6. Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, 
Brown B, Berger BD, O’Connor JK, Goldstein RM. 
Hepatocellular carcinoma: management of an increas-
ingly common problem. Proc (Bayl Univ Med Cent). 2008; 
21:266–280.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, 
Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, 
et al. Efficacy and safety of sorafenib in patients in the 
Oncotarget17158www.impactjournals.com/oncotarget
Asia-Pacific region with advanced hepatocellular carci-
noma: a phase III randomised, double-blind, placebo-con-
trolled trial. Lancet Oncol. 2009; 10:25–34.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, 
Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, 
Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in 
advanced hepatocellular carcinoma. N Engl J Med. 2008; 
359:378–390.
9. Kim R, Byrne MT, Tan A, Aucejo F. What is the indica-
tion for sorafenib in hepatocellular carcinoma? A clinical 
 challenge. Oncology (Williston Park). 2011; 25:283–291.
10. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, 
Kurzrock R. Identification of novel therapeutic targets in 
the PI3K/AKT/mTOR pathway in hepatocellular carcinoma 
using targeted next generation sequencing. Oncotarget. 
2014; 5:3012–3022.
11. Katanasaka Y, Kodera Y, Yunokawa M, Kitamura Y, 
Tamura T, Koizumi F. Synergistic anti-tumor effects of 
a novel phosphatidyl inositol-3 kinase/mammalian tar-
get of rapamycin dual inhibitor BGT226 and gefitinib in 
non-small cell lung cancer cell lines. Cancer Lett. 2014; 
347:196–203.
12. Janes MR, Fruman DA. Targeting TOR dependence in 
 cancer. Oncotarget. 2010; 1:69–76.
13. Eyre TA, Collins GP, Goldstone AH, Cwynarski K. 
Time now to TORC the TORC? New developments in 
mTOR pathway inhibition in lymphoid malignancies. Br J 
Haematol. 2014; 166:336–351.
14. Shiojima I, Walsh K. Regulation of cardiac growth and 
coronary angiogenesis by the Akt/PKB signaling pathway. 
Genes & development. 2006; 20:3347–3365.
15. Jiang BH, Liu LZ. AKT signaling in regulating angiogen-
esis. Curr Drug Targets. 2008; 8:19–26.
16. Brown JM. Tumor hypoxia in cancer therapy. Methods 
Enzymol. 2007; 435:297–321.
17. Choi SB, Park JB, Song TJ, Choi SY. Molecular mechanism 
of HIF-1-independent VEGF expression in a hepatocellular 
carcinoma cell line. Int J Mol Med. 2011; 28:449–454.
18. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, 
Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, 
Anak O, Hackl W, Baselga J. Phase I safety, pharmaco-
kinetic, and pharmacodynamic study of the oral phospha-
tidylinositol-3-kinase and mTOR inhibitor BGT226 in 
patients with advanced solid tumors. Ann Oncol. 2012; 
23:2399–2408.
19. Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, 
Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG. 
Differential effects of selective inhibitors targeting the 
PI3K/AKT/mTOR pathway in acute lymphoblastic leuke-
mia. PloS one. 2013; 8:e80070.
20. Lee JH, Lee H, Yun SM, Jung KH, Jeong Y, Yan HH, 
Hong S, Hong SS. IPD-196, a novel phosphatidylinositol 
3-kinase inhibitor with potent anticancer activity against 
hepatocellular carcinoma. Cancer Lett. 2013; 329:99–108.
21. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, 
McCubrey JA, Capitani S, Neri LM. The AKT inhibitor 
MK-2206 is cytotoxic in hepatocarcinoma cells displaying 
hyperphosphorylated AKT-1 and synergizes with conven-
tional chemotherapy. Oncotarget. 2013; 4:1496–1506.
22. Chang AY, Wang M. Molecular mechanisms of action 
and potential biomarkers of growth inhibition of dasatinib 
(BMS-354825) on hepatocellular carcinoma cells. BMC 
cancer. 2013; 13:267.
23. Wang J, Zheng X, Zeng G, Zhou Y, Yuan H. Purified vitexin 
compound 1 inhibits growth and angiogenesis through acti-
vation of FOXO3a by inactivation of Akt in hepatocellular 
carcinoma. Int J Mol Med. 2014; 33:441–448.
24. Wilson JM, Kunnimalaiyaan S, Gamblin TC, 
Kunnimalaiyaan M. MK2206 inhibits hepatocellular carci-
noma cellular proliferation via induction of apoptosis and 
cell cycle arrest. J Surg Res. 2014; 191:280–285.
25. Grabinski N, Ewald F, Hofmann BT, Staufer K, 
Schumacher U, Nashan B, Jucker M. Combined targeting 
of AKT and mTOR synergistically inhibits proliferation of 
hepatocellular carcinoma cells. Mol Cancer. 2012; 11:85.
26. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, 
Chang JY. Novel phosphoinositide 3-kinase/mTOR dual 
inhibitor, NVP-BGT226, displays potent growth-inhibitory 
activity against human head and neck cancer cells in vitro 
and in vivo. Clin Cancer Res. 2011; 17:7116–7126.
27. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, 
Schmidmaier R. Simultaneous targeting of PI3K and mTOR 
with NVP-BGT226 is highly effective in multiple myeloma. 
Anti-cancer Drugs. 2012; 23:131–138.
28. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, 
Phommaly C, Gao F, Lin L, Ellis MJ. Preclinical  modeling 
of combined phosphatidylinositol-3-kinase inhibition with 
endocrine therapy for estrogen receptor-positive breast 
 cancer. BCR. 2011; 13:R21.
29. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, 
Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. 
NVP-BEZ235 and NVP-BGT226, dual phosphatidylino-
sitol 3-kinase/mammalian target of rapamycin inhibitors, 
enhance tumor and endothelial cell radiosensitivity. Radiat 
Oncol. 2012; 7:48.
30. Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3K/
mTOR inhibitor NVP-BGT226 induces cell cycle arrest and 
regulates Survivin gene expression in human pancreatic 
cancer cell lines. Tumour Biol. 2012; 33:757–765.
31. Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X, Chen J, 
Jin J. 10058-F4, a c-Myc inhibitor, markedly increases 
valproic acid-induced cell death in Jurkat and CCRF-
CEM T-lymphoblastic leukemia cells. Oncol Lett. 2014; 
8:1355–1359.
32. Wallington-Beddoe CT, Hewson J, Bradstock KF, 
Bendall LJ. FTY720 produces caspase-independent cell 
death of acute lymphoblastic leukemia cells. Autophagy. 
2011; 7:707–715.
Oncotarget17159www.impactjournals.com/oncotarget
33. Pankiv S, Clausen TH, Lamark T, Brech A, BruunJA, 
Outzen H, Overvatn A, Bjorkoy G, Johansen T. p62/
SQSTM1 binds directly to Atg8/LC3 to facilitate 
 degradation of ubiquitinated protein aggregates by autoph-
agy. J Biol Chem. 2007; 282:24131–24145.
34. Kung CP, Budina A, Balaburski G, Bergenstock MK, 
Murphy M. Autophagy in tumor suppression and cancer 
therapy. Crit Rev Eucaryot Gene Expr. 2011; 21:71–100.
35. Wang L, Gao C, Yao S, Xie B. Blocking autophagic flux 
enhances matrine-induced apoptosis in human hepatoma 
cells. Int J Mol Sci. 2013; 14:23212–23230.
36. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, 
Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, 
Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, 
Ait-Si-Ali S, et al. Guidelines for the use and interpretation of 
assays for monitoring autophagy. Autophagy. 2012; 8:445–544.
37. Harris AL. Hypoxia–a key regulatory factor in tumour 
growth. Nat Rev Cancer. 2002; 2:38–47.
38. Weinmann M, Jendrossek V, Handrick R, Guner D, 
Goecke B, Belka C. Molecular ordering of hypoxia-induced 
apoptosis: critical involvement of the mitochondrial death 
pathway in a FADD/caspase-8 independent manner. 
Oncogene. 2004; 23:3757–3769.
39. Nagarajah NS, Vigneswaran N, Zacharias W. Hypoxia-
mediated apoptosis in oral carcinoma cells occurs via two 
independent pathways. Mol Cancer. 2004; 3:38.
40. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, 
Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, 
D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, 
Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/
AKT pathways in malignant transformation and drug resis-
tance. Adv Enzyme Regul. 2006; 46:249–279.
41. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB 
(Akt) pathway in cell cycle progression. Cell Cycle. 2003; 
2:339–345.
42. Steelman LS, Chappell WH, Abrams SL, Kempf RC, 
Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, 
Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte 
G, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/
mTOR pathways in controlling growth and sensitivity to 
therapy-implications for cancer and aging. Aging. 2011; 
3:192–222.
43. Ruan ZP, Xu R, Lv Y, Tian T, Wang WJ, Guo H, Nan KJ. 
PTEN enhances the sensitivity of human hepatocellular car-
cinoma cells to sorafenib. Oncol Res. 2012; 20:113–121.
44. O’Brien C, Wallin JJ, Sampath D, GuhaThakurta D, 
Savage H, Punnoose EA, Guan J, Berry L, Prior WW, 
Amler LC, Belvin M, Friedman LS, Lackner MR. 
Predictive biomarkers of sensitivity to the phosphatidylino-
sitol 3’ kinase inhibitor GDC-0941 in breast cancer preclini-
cal models. Clin Cancer Res. 2010; 16:3670–3683.
45. Liang X, Tang J, Liang Y, Jin R, Cai X. Suppression of 
autophagy by chloroquine sensitizes 5-fluorouracil- mediated 
cell death in gallbladder carcinoma cells. Cell & Bioscience. 
2014; 4:10.
46. Xu ZX, Liang J, Haridas V, Gaikwad A, Connolly FP, 
Mills GB, Gutterman JU. A plant triterpenoid, avicin D, 
induces autophagy by activation of AMP-activated protein 
kinase. Cell Death Differ. 2007; 14:1948–1957.
47. Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. 
Nilotinib induces autophagy in hepatocellular  carcinoma through 
AMPK activation. J Biol Chem. 2013; 288:18249–18259.
48. Martins I, Galluzzi L, Kroemer G. Hormesis, cell death and 
aging. Aging. 2011; 3:821–828.
49. Evangelisti C, Chiarini F, Lonetti A, Buontempo F, 
Neri LM, McCubrey JA, Martelli AM. Autophagy in acute 
leukemias: a double-edged sword with important therapeu-
tic implications. Biochim Biophys Acta. 2015; 1853:14–26.
50. Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. 
From nature to bedside: pro-survival and cell death mecha-
nisms as therapeutic targets in cancer treatment. Biotechnol 
Adv. 2014; 32:1111–1122.
51. Abdel-Aziz AK, Shouman S, El-Demerdash E, Elgendy M, 
Abdel-Naim AB. Chloroquine synergizes sunitinib cytotox-
icity via modulating autophagic, apoptotic and angiogenic 
machineries. Chem Biol Interact. 2014; 217:28–40.
52. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, 
Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. 
Cell cycle-dependent activity of the novel dual PI3K-
MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol 
Cancer. 2013; 12:46.
53. Shah AT, Demory Beckler M, Walsh AJ, Jones WP, 
Pohlmann PR, Skala MC. Optical metabolic imaging of 
treatment response in human head and neck squamous cell 
carcinoma. PloS one. 2014; 9:e90746.
54. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C. Gefitinib 
 resistance in HCC mahlavu cells: upregulation of CD133 
expression, activation of IGF-1R signaling pathway, and 
enhancement of IGF-1R nuclear translocation. J Cell 
Physiol. 2012; 227:2947–2952.
55. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, 
Gores GJ. Hypoxia stimulates proliferation of human 
 hepatoma cells through the induction of hexokinase II 
expression. J Hepatol. 2005; 42:358–364.
56. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. 
Insulin-like growth factor II induced by hypoxia may 
 contribute to angiogenesis of human hepatocellular carci-
noma. Cancer Res. 1998; 58:348–351.
57. Mazure NM, Nguyen TL, Danan JL. Severe hypoxia 
 specifically downregulates hepatocyte nuclear factor-4 gene 
expression in HepG2 human hepatoma cells. Tumour Biol. 
2001; 22:310–317.
58. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, 
Kim KW. Hypoxia-induced VEGF enhances tumor sur-
vivability via suppression of serum deprivation-induced 
 apoptosis. Oncogene. 2000; 19:4621–4631.
Oncotarget17160www.impactjournals.com/oncotarget
59. Mudie S, Bandarra D, Batie M, Biddlestone J, Moniz S, 
Ortmann B, Shmakova A, Rocha S. PITX1, a specificity 
determinant in the HIF-1alpha-mediated transcriptional 
response to hypoxia. Cell Cycle. 2014; 13:3878–3891.
60. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev 
Cancer. 2003; 3:721–732.
61. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-
inducible factor 1 is a basic-helix-loop-helix-PAS heterodi-
mer regulated by cellular O2 tension. Proc Natl Acad Sci U 
S A. 1995; 92:5510–5514.
62. Cui SY, Huang JY, Chen YT, Song HZ, Huang GC, De W, 
Wang R, Chen LB. The role of Aurora A in hypoxia- 
inducible factor 1alpha-promoting malignant phenotypes of 
hepatocelluar carcinoma. Cell Cycle. 2013; 12:2849–2866.
63. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van 
Oosterom AT, De Bruijn EA. Vascular endothelial growth 
factor and angiogenesis. Pharmacol Rev. 2004; 56:549–580.
64. Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, 
Lee HS, Hong SS. HS-116, a novel phosphatidylinosi-
tol 3-kinase inhibitor induces apoptosis and suppresses 
angiogenesis of hepatocellular carcinoma through inhibi-
tion of the PI3K/AKT/mTOR pathway. Cancer Lett. 2012; 
316:187–195.
65. Cikla-Suzgun P, Kaushik-Basu N, Basu A, Arora P, 
Talele TT, Durmaz I, Cetin-Atalay R, Kucukguzel SG. 
Anti-cancer and anti-hepatitis C virus NS5B polymerase 
activity of etodolac 1,4-triazoles. J Enzyme Inhib Med 
Chem. 2015; 2:1–8.
66. Tuncbilek M, Guven EB, Onder T, Cetin Atalay R. 
Synthesis of novel 6-(4-substituted piperazine-1-yl)-
9-(beta-D-ribofuranosyl)purine derivatives, which lead to 
senescence-induced cell death in liver cancer cells. J Med 
Chem. 2012; 55:3058–3065.
67. Buontempo F, Ersahin T, Missiroli S, Senturk S, Etro D, 
Ozturk M, Capitani S, Cetin-Atalay R, Neri ML. Inhibition 
of Akt signaling in hepatoma cells induces apoptotic cell 
death independent of Akt activation status. Invest New 
Drugs. 2011; 29:1303–1313.
68. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, 
Domany E, Yaffe MB, Strano S, Blandino G, Di 
Agostino S. Mutant p53 oncogenic functions are sustained 
by Plk2 kinase through an autoregulatory feedback loop. 
Cell Cycle. 2011; 10:4330–4340.
69. Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, 
Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, 
Pagliaro P, Iacobucci I, Martinelli G, et al. A combination 
of temsirolimus, an allosteric mTOR inhibitor, with clo-
farabine as a new therapeutic option for patients with acute 
myeloid leukemia. Oncotarget. 2012; 3:1615–1628.
70. Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, 
Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, 
Pession A, McCubrey JA, Martelli AM. Harnessing the 
PI3K/Akt/mTOR pathway in T-cell acute lymphoblas-
tic leukemia: eliminating activity by targeting at different 
 levels. Oncotarget. 2012; 3:811–823.
71. Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, 
Gladkich J, Nwaeburu CC, Mattern J, Mollenhauer M, 
Ruckert F, Zach S, Haberkorn U, et al. Inhibition of glu-
cose turnover by 3-bromopyruvate counteracts pancreatic 
cancer stem cell features and sensitizes cells to gemcitabine. 
Oncotarget. 2014; 5:5177–5189.
72. Sparta AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, 
Evangelisti C, Melchionda F, Pession A, Bertaina A, 
Locatelli F, McCubrey JA, Martelli AM. Therapeutic target-
ing of Polo-like kinase-1 and Aurora kinases in T-cell acute 
lymphoblastic leukemia. Cell Cycle. 2014; 13:2237–2247.
